Hosted by Professor Ian M. Gralnek
Raf Bisschops: Raf Bisschops it is becoming clear that we can actually push that boundary further So I think that is in fact the biggest change for the last ten years.
Intro: Intro Welcome to the ESGE podcast, Endoscopy Unplugged, Join us each month to hear the latest from European experts and where we'll discuss relevant clinical topics and provide you with tips and tricks, practical scientific evidence and pearls of wisdom to inform your endoscopy practice. So please subscribe wherever you get your podcasts and join us as we advance GI endoscopy care.
Ian: Ian Hello, everyone, and welcome to episode eleven of ESG's podcast, Endoscopy Unplugged. My name is Ian Gralneck, past president of the ESGE, and I'm your host. Today's podcast is entitled Endoscopic Therapy for Barrett's esophagus. What's in your toolbox? And my guest today is Professor Raf Bisschops who is head of the endoscopy department at the University Hospitals in Leuven, in Leuven, Belgium. And he is also the president elect of the ESGE. Welcome, Raf to the podcast. It's great to have you here.
Raf Bisschops: Raf Bisschops Thank you Ian for having me. It's it's a pleasure being here today.
Ian: Ian Raf, of course, is a well known international expert on Barrett's esophagus, including endoscopic therapies for Barrett's esophagus. And that's what we're gonna really focus on today, Raf. But before we get to that discussion, tell us how did you get into GI endoscopy?
Raf Bisschops: Raf Bisschops Well actually I decided during my second year of fellowship when I was still into internal medicine that I really wanted to do gastroenterology. And one of the aspects that was attractive to me was in fact that you also have the technicalities of the endoscopy. And during my last year they actually asked me whether I want to stay at the university to further develop new techniques and new and do studies with new imaging modalities. So and that's how I ended up doing this, what I'm doing now.
Ian: Ian Well, it's it's a great benefit to all of us that you decided to be in GI Endoscopy. You've been an author on multiple, multiple important manuscripts, so let let's get at this. what do you think is the biggest change in how we manage Barret's esophagus today compared to let's say a decade ago.
Raf Bisschops: Raf Bisschops Well, I think it's been long established now that we can treat early neoplasia endoscopically. So I think if we look at the last ten year specifically, what you're asking, the major change is that we have finally found an indication for endoscopic submucosal dissection in Barretts. Resection of visible lesions has always been the cornerstone of a successful treatment in Barrett's. But for a long time there was this long winding discussions about whether we should do ESD or not. Discussions that were actually sometimes quite heated and emotional by people who are really big believers and were more focusing on the on-block thing. But nowadays we have realized that well, pushing the boundaries for endoscopic treatment into the submucosa for early baris neoplasia, that is where the real indication for ESD has found its place. And now it makes sense. Because actually the evidence still shows that endoscopic mucosal resection works perfectly, especially for mucosal cancer. But that goes back to the fact that when you have a submucosal lesion in the past, that would lead immediately to an esophagectomy. And now with the new data that we have from the preferred trial, it is becoming clear that we can actually push that boundary further and for those lesions we can have a a better on block resection and R0 resection if we apply ESD. So I think that is in fact the biggest change for the last ten years.
Ian: Ian Yeah, we're gonna we'll get to that a bit more down the road in this podcast. But let let's start with for non dysplastic Barrett’s. the guideline is surveillance rather than treatment.
Raf Bisschops: Raf Bisschops Mm-hmm.
Ian: Ian do you agree with that or is there any circumstance where you'd consider ablating a patient who has Barrett's but no dysplasia?
Raf Bisschops: Raf Bisschops In the twenty years that I do this treatment, I've only treated one patient with non-dysplastic Barrett's. And I think in general the risk of developing cancer once Barrett's has been detected is is rather low. I always mention to my patients and compare this for instance to the risk of colorectal cancer or breast cancers in women. The fact is that the long lifetime risk for Barrett's cancer development is about five to seven percent for an individual. And if you compare that to the risk of colorectal cancer, which is also seven percent from the time you're born, or for women for getting breast cancer to 10 to 12%. And if you mention those figures to the patients, most of the time they're quite reassured because nobody loses any sleep about getting colorectal cancer while they all have a colon. So that's quite reassuring and because of that it is obviously doesn't make sense to ablate everybody because you probably would do more harm. And there's another thing to it is that if you do it, you're not entirely sure that you're gonna prevent cancer. In fact, there's an old study with APC indicating that the risk of developing cancer twenty years later is just as high as as not treating the Barrett’s in the first place. So these things all together make it really not cost effective in the long term. And so in principle, none of this plastic barrier should be followed up. So the only exception I can think about is if you have a a relatively young patient with a very long segment barriers and with a lot of first degree relatives and family history of of adenocarcinoma where you might consider doing this because they have a higher risk profile to develop that and you could probably do a preventive measure in those patients that make sense.
Ian: Ian Okay. So those patients are very, very rare, as rare as hens teeth. So the the takeaway message here is really in almost everybody, non-dysplastic Barrett’s does not require any type of ablation therapy. Let's move on now to low grade dysplasia. So, you know, guidelines say that if you get low grade dysplasia on a biopsy, you really need to have that confirmed by two separate, on two separate endoscopies and by experienced pathologists before you're gonna offer ablation. What why? Tell us why that is.
Raf Bisschops: Raf Bisschops Well, the bottom line is basically the same reasoning as a non-dysplastic Barrett’s. So you don't want to over treat patients that don't need it. A low grade dysplasia, unfortunately, is a very difficult diagnosis to make by pathologists. So all pathologists see many, many, many normal non dysplastic Barrett’s, and then all of a sudden comes along this inflamed biopsy that looks very irregular, and they classify it as as as low grade dysplasia. And it has been clearly shown that if these biopsies are then downgraded by an expert pathologist to non-dysplastic, that in those cases actually the risk is similar to non-dysplastic barriers. So that therefore we need the confirmation of an experienced pathologist. And also it goes back basically to the inclusion criteria of the SURF trial. That was a trial that compared follow-up versus active radio frequency ablations in patients with confirmed low grade dysplasia. And they had needed this confirmation on two separate occasions by experienced pathologists. And in that particular case, we know that the risk actually increases to about 25% over a two-year period to go from low grade to high grade dysplasia or early cancer. So if you want to consider ablation in patients with low grade dysplasia, at least you need to make sure that the risk in that patient is indeed increased, that in the next following two, three years. They will develop the next stage of high grade dysplasia or early adenocarcinoma. And that is why we want to have this confirmed.
Ian: Ian So so if you've done that first endoscopy and it comes back as low grade dysplasia, what do you do before you do the next endoscopy to confirm that low grade dysplasia? Do you put them on high dose PPIs?
Raf Bisschops: Raf Bisschops Yeah, that is indeed very important, Ian and so the inflammation we need to make sure that most of it is gone. So and the best way to do that is then to give a long period of high dose PPI. So what we do in practice, usually after three to four months of high dose PPI, we see the patients back and then we check how the oesophagus looks. So first we want to rule out inflammation because a confounder. The second thing is, however, if that low grade dysplastic biopsy has already been confirmed by our experienced pathologist, then we also want to rule out more severe disease. Because I might you I just have said that very often the low grade dysplasia is overestimated in terms of risk. But on the other hand, it can also be underestimated once it has been confirmed by expert pathologists. A recent study from the Dutch group showed that if you call these patients with confirmed low-grade dysplasia, back and have an experienced endoscopist look at the esophagus, you can find in 23% of them within three months high-grade dysplasia or the cancer. So, on the one hand, it may be like something innocent if you don't have it confirmed by an experienced pathologist. But once it is confirmed, you definitely need to make sure that that isn't just a marker of more prevalent disease. So you need to need to look thoroughly in that esophagus to rule out visible lesion and worse pathology than the low great dysplasia. So I think these are the two major points. First, rule out it's not something innocent. And second, rule out if it there's nothing worse going on.
Ian: Ian Okay, so that second endoscopy is exceedingly important.
Raf Bisschops: Raf Bisschops Mm-hmm.
Ian: Ian So you want to make sure that also the patients are well prepared, you have a clean esophagus. Do you some do you use something to clean the esophagus before you evaluate?
Raf Bisschops: Raf Bisschops Yeah, we usually use water and stemethicon that suffices. You can also use something like mucomist. bottom line is for any and basically this is not only the case for referral endoscopies for dysplasia. This should be a default setting for any Barrett’s endoscopy that you do, that you really clean the Barrett’s esophagus as as as good as possible so that you have good visibility to find any start of lesion that might be there.
Ian: Ian now you've had this patient, you you're sure there's low grade dysplasia, they've had the second endoscopy, there's nothing else sinister going on, there's no high grade dysplasia. what are you gonna do at that point? Are you gonna ablate that patient or are you just gonna intensify your surveillance?
Raf Bisschops: Raf Bisschops That's a very good point, Ian. So I think what you need to do down need to do then is to sit down with your patient and discuss what can be done. So and usually I take about half an hour to explain the SURF trial to these patients, what the results are, whether they are amongst those amongst this group of patients, whether they're similar. And then I discussed the risk of progression, which I just mentioned was 23% over a two-year period.
Ian: Ian Mm-hmm.
Raf Bisschops: Raf Bisschops And what I often do with these patients is then flip around that coin and say, you can also say that's in 75% of the cases, nothing happens. And in fact, uh
Ian: Ian Right.
Raf Bisschops: Raf Bisschops many patients find that quite reassuring. And with that respect, we also need to take into consideration not to cause any more harm. So if the patient has significant comorbidities, then we definitely take that into consideration and rather go for a longer or more intensify surveillance and see what happens in the future. I think the bottom line here is that if you're sure there's nothing worse going on in the biopsies and you're absolutely sure there's no visible lesion that needs removal, in that case you do have time to do the therapy. And I think it's also important to emphasize that in the SURF trial for those who progressed in the in the follow-up arm, they didn't they never needed any surgeries. So you have all the time to still provide your endoluminal therapy. So you need to discuss this very thoroughly and honestly with your patient and give him or her all the options that are there, including the surveillance. And it depends a little bit on how they perceive that risk. If if they feel this is like a a Damocles’’ sword above their hat and they are very afraid about it, they probably will go for ablation, or they say, I don't want to have all the surveillance and uncertainty. So there are many factors that eventually lead to a certain decision by the patient. And I think most of the patients are clever enough to understand and to make a decision together with you.
Ian: Ian Okay. let's go to high grade dysplasia and and early cancer. So high grade dysplasia that's found on biopsy and confirmed, but there's no visible lesion, it's straight to ablation. But what happens when you see a visible lesion? What what's what's your practice?
Raf Bisschops: Raf Bisschops Well, I think that's the most important key point to take home for any treatment in Barrett's is that if you have that situation with a visible lesion that so called only shows high grade dysplasia, EMR should be performed. So EMR or endoscopic resection in general, whether you do it with ESD or EMR, is indeed the cornerstone of a successful treatment in in Barrett's neoplasia. And that has been clearly demonstrated throughout all the trials that have been conducted. So there is not a single study that included visible lesions for ablation. So all the major studies, like for instance the EURO II trial, the SURF trial, there was first removal of all visible lesions. and in fact, the data that we that were included in the UK registry clearly showed that if the rate of EMR goes up to about 60% in this specific group, then the success rate of the treatment also increases significantly. And this rate should be in this specific situation, if you're dealing with patients with high grade dysplasia, the EMR rate should be around 60%. And this is a apparently a figure that comes back consistently in many registries, like for instance the Dutch registry, the UK registry, and also our own Belgian registry.
Ian: Ian Okay. And we'll we'll talk about the type of ablation that's available in just a few minutes. But I wanna go go get a little bit deeper into the weeds here. What's your decision process if you find a T1a cancer? What what do you do at this point? Is is resection, endoscopic resection curative, or just talk our listeners through that process?
Raf Bisschops: Raf Bisschops Yeah, so first of all, if you find it on biopsy, you're never sure what you're going to end up with. So you cannot basically make correct diagnosis before you take out the lesion. So if cancer is shown on a biopsy, it's definitely not a contraindication to go ahead with a resection, whether it's EMR or ESD. So we usually have to wait until the final pathology comes back from the resection specimen. And if that shows indeed a mucosal cancer that is well well too moderately differentiated and no lymphovascular invasion, we call as a this a curative resection. and we don't do any specific follow-up for that particular lesion anymore. So in the past, when we started this, we do we would do systematic endosonography, we would do even do systematic PET CTs after six and twelve months. But we learned from that experience that it basically only shows second primary lesions and nothing that has to do with the initial cancer as such. So we've completely abandoned this. So this is something that you take out like a polyp, and there's no need for additional imaging.
Ian: Ian So but you but you're continuing to do surveillance endoscopies afterwards.
Raf Bisschops: Raf Bisschops No, we continue in most cases with radio frequency ablation or any other ablation therapy, and that is
Ian: Ian Right.
Raf Bisschops: Raf Bisschops to that is to reduce the risk of recurrence. So what we learned from this practice, and actually the first study to show this was an a study with APC from the Wiesbaden group again, and it shows if you eradicate all the remaining Barrett’s you you reduce the risk of metachronic disease from about thirty percent. To 2.0%, so less than 3%. And that is the ideal concept now. So the first step is to resect all the visible lesions. And the second step of a Barrett's treatment is then to eradicate all the residual Barrett’s, which in most cases is actually non-dysplastic. But we know that if you don't do that, there is a 30% chance in the next two, three years that a similar lesion will appear that needs additional treatment. And that's why this is now the gold standard.
Ian: Ian Okay, so now let me challenge you a little bit further. What about if it's a T1b after you've done a resection?
Raf Bisschops: Raf Bisschops Yeah. I think that's a different story. I think here we need to le be a little bit careful. and definitely you need to sit down with the patient and discuss what you're gonna do further. So we had the pleasure to participate in the PREFER trial, which is a a big prognostic follow-up study led by Roos Pouw for these specific lesions, not only low-risk submucosal lesions, but any submucosal lesion, even with poor prognosticators. And and this is really like something a game changer, where the field of ESD has become important to get radical resections. So, here we need to be more careful because indeed there is an increased risk of developing noid metastasis or even distant metastasis over time, and that is something that we need to take into consideration. So the risk in itself is lower than previously anticipated. So in the past it was a thought that the risk for submucosal invasion went up to maybe 30 40 percent if you have a submucosally invading lesion. But we know now actually that this risk is significantly lower thanks to the PREFER trial. Nonetheless I think in the beginning they were a little bit conservative in the follow-up so we we we would do endosonography every three months for the first two years, and then every six months after that. And there was only one PAT CT or CT planned after 12 months. But we have now like three-year follow-up, and actually, there were three patients identified with late distant metastasis 30 months after the resection. And so the idea is that these patients might actually have been picked up earlier if more CTs were conducted, because there were no signs of lymph node metastasis on the endosonography. So here I think the paradigm, if you follow up these patients, you should do this under strict protocol within the setting of an MDT that that is also applying and accepting this kind of follow up and then also with a strict follow up with expert endosonography and at least every 12 months a PET CT or a regular CT to to check if there are still distant metastasis. The total risk of this is higher than in mucosal disease. So there's about a 6 to 10% risk of lymph node metastasis and a 4% risk of distant metastasis in case of a high-risk T1B. So here the follow-up is definitely different and needs to be more thorough in order to provide other therapies to the patients when this happens.
Ian: Ian And the patients really need a a good explanation of this, of of of of the importance of of the risk and the change and and how they need to be on a very short leash for follow up, correct? Yeah.
Raf Bisschops: Raf Bisschops Yeah, absolutely. And it I was a little bit worried when we started this trial if if patients would accept that, because obviously the risk is higher. But the fact is that if you explain to the patients now with the numbers we have and that we anticipated at that time that you have a ninety percent chance of being cured of cancer, and especially that they would undergo a a a resection over the esophagus and the lymph nodes with a very high chance of not finding anything related to that disease that actually leads to the to most of the patients that they they saying that they don't want to have in esophagectomy after a radical resection of a T1B cancer. I was actually I don't I I don't think a single patient was operated unless recurrence was found in these patients. And that is still possible. So if they have recurrence or lymph node metastasis, it doesn't mean that they cannot be treated anymore with additional therapies.
Ian: Ian Yeah, this is a major change in the clinical management of these patients. let me ask you about the ablation, the endoscopic ablation techniques, radio frequency ablation, RFA versus cryotherapy. What what's your usual go to for ablation? What do you do?
Raf Bisschops: Raf Bisschops Well, we usually use radio frequency ablation because we have the most experience with that. And I think it's also the best studied modality. But obviously not everybody has access to that, and there's currently also good evidence showing that hybrid APC can work, and also for cryotherapy, especially with the balloon-based cryotherapy, and they are all available on the market. I think maybe cryo has a little bit less pain response, but stricture rate are all around five to ten percent, no matter what technique that you apply. I think the bottom line is that you need to be trained in the technique that you used. And I think the problem there I find with APC is that sometimes people mistake the easy accessibility of a technique for the easiness of the application of the technique in that particular situation. So I think it's quite challenging for a very long segment barrier to be very well treated with APC. So you need to have a good training if you do that and follow the certain protocols that have been defined.
Ian: Ian So how do you get trained? What what if I were to wanted to do this, what do I need to do?
Raf Bisschops: Raf Bisschops I think the most important thing is to get a training in optical diagnosis and detection of lesions, because as I said before, the the cornerstone of a of an effective treatment in Barret's neoplasia is to find the needle in the haystack. And that means you really, really need to be good at looking and for these lesions and identify subtle elevated or flat lesions that need removal. And I think you the only way you can do that is by seeing a lot of patients and following a lot of patients before you are left on your own. There is actually some guidance there in the ESGE guideline and the BSG guidelines that says that you need to do 30 EMRs and 30 RFAs supervised in order to become proficient at this. But it's just an estimated figure, but it's something that you can actually apply. And in fact, for our specific Belgian situation, this is included for the recognition of these Barrett’s centres that the person who does the endolumotherapy has indeed this experience. In addition, also. to the fact that you need to have at least ten patients with new neoplasia every year in order to maintain your competence.
Ian: Ian So after you know, after you do an ablation, whether it's radio frequency or cryotherapy or APC, are are you putting patients on a a specific type of a protocol? Do you put them on steroids afterwards to try and prevent stricture formation or anything?
Raf Bisschops: Raf Bisschops No, I think the only thing we do is just basic double dose PPI therapy. There's there's no data yet on on budesonide slurries or something like that. Would be interesting to investigate that, especially those patients who've had previous resections because the risk is a bit higher in those patients, goes up to twelve percent. but besides double dose PPI, we don't give anything else.
Ian: Ian I actually I wanna I wanna go back just for a second. So i after you've done a resection, whether it's ESD or EMR, how long do you wait before you then do the ablation?
Raf Bisschops: Raf Bisschops we allow at least six weeks of interval and it also depends a little bit on the extent of the resection. So for small lesions, this is usually healed up in in six months. But if you've done a very extensive resection over several centimetres and more than fifty percent of the circumference, we very often leave at least twelve weeks in between.
Ian: Ian Okay. Okay. And then you bring them back and you you start the ablation. Okay.
Raf Bisschops: Raf Bisschops Yes, yeah.
Ian: Ian What do you see as sort of the biggest technical pitfall of other endoscopists make with with ablation or resection techniques?
Raf Bisschops: Raf Bisschops I think the biggest pitfall is missing the lesion. So honestly that is that is
Ian: Ian So not so not e so not even ablation or resection is actually just missing what's there. Okay.
Raf Bisschops: Raf Bisschops Yeah, I think once you I mean you can learn resections, I mean you like you can learn polypectomy. That's not the most difficult thing, especially for EMR. The most difficult part, I think, is to to properly delineate lesions and to find them, right? And and that clearly shows in in many referrals that we get with known dysplasia, the visible lesion has not been identified. You can argue that that they developed over eight weeks' time, but I think that will not be the case in everybody. So I think that is the biggest challenge in general for for endoluminal treatment of Barrett’s because you don't want to ablate cancer because it won't work and you may actually worsen everything for the patient and take away the opportunity for an organ-saving therapy. Another technical issue is that you apply the wrong protocol. So the ablation protocols need to be known and especially if you go into the literature alone, you may get a little bit confused. So I think specifically for RAVA, there are good training programs that are set up where you can learn all about the dosimetry of of the radio frequency ablation and that is really important because the some of the older trials actually use use other dosimetry than what we are currently advising. And the same goes for argon plasma correlation. As I said before, it's not not because it's easily accessible that it's easily applied. So this also needs like a a a double hit. So you clean at a cer at a higher setting, you clean, and then you apply a second hit. So really go through the correct protocols and know which energy to apply and how to apply the correct technique. Because the technique in itself is easy, but if you don't use the correct dosimetry, you may actually under treat your patient.
Ian: Ian That's an important point. if you could get, you know, an endoscopist to really take one thing away from I think the ESGE guidelines or the BSG guidelines on resection and ablation and Barrett’s, what what would it be in your opinion?
Raf Bisschops: Raf Bisschops There's just one improve your quality of daily endoscopy. That's it. So they
Ian: Ian Okay.
Raf Bisschops: Raf Bisschops need to they need to clean the esophagus, they need to take that time to look and inspect and try to find lesions. Because in the past, I mean people didn't care that much because these patients were getting old, they would end up with surgery, which they usually couldn't take. but nowadays if you can detect these lesions at an early stage, you can actually provide an organ-saving therapy. So therefore, surveillance. And if you do it then, the quality of that surveillance has become even more important. And I think just taking those extra five to six minutes to look properly at the esophagus, to clean it, to take those pictures and document photo document, and then finally actually take the Seattle biopsy protocol and not just take four biopsies out of a ten centimetre Barrett’s, I think for the all the patients with barrels out there, that would be the most important thing to adapt from the ESGE guideline.
Ian: Ian You're you're routinely using w I mean, I know you use high definition white light scopes with near focus, but what about the use of things such as NBI or I scan, et cetera, stuff like that. You routinely use that as part of your evaluation, I assume?
Raf Bisschops: Raf Bisschops yes, absolutely I do. So I think that's all we included that also now in the in the guideline that every Barrett’s esophagus should be inspected with some form of chromoendoscopy, whether it's virtual chromoendoscopy or acidic acid chromoendoscopy. and although the there is no evidence showing that it increases detection, it has to do with what you with with increasing the inspection time. If you use these techniques, you need to make sure the esophagus is clean. if you use these techniques and you switch Between white light and virtual chromoendoscopy mode, it will take more time. So you will spend more time looking. And I think all these things together will not only lead to a longer inspection, but in the end also a better inspection. So that was the reasoning why we included this and why, although there is actually little evidence to support the use of these techniques.
Ian: Ian Listen, Raf, this has been a great podcast. you've given a lot of tips and tricks and great information. I also want to congratulate you on your upcoming presidency of the ESGE. You'll take over at the end of ESGE days in the end of April this year, which is great. And I've really enjoyed serving with you on the governing board and the executive committee of the ESGE. For these past, I think now it's been eight years we've been there together. Now in addition, we also want to know what what do you do outside the endoscopy suite? I know because we've known each other for a long time, you're into trance music. God only knows why you're into trance music.
Raf Bisschops: Raf Bisschops Yeah.
Ian: Ian but you are into trance music. But w what else, what else do you do when you're not listening to that crazy trance music?
Raf Bisschops: Raf Bisschops Well, I I do like music a lot, yeah, not only trans music, so the reason why I like trans is basically very often you you know, you've heard about your musical DNA, right? And my musical DNA is New Order, Blue Monday. And anything that comes with some kind of ominous sound and a good beat underneath it is something that really triggers me. And I think that's why I I like it. It's it's it's almost like you get like into a trance if you if you listen to this technomusic so that's why I like it. Uh also
Ian: Ian Okay.
Raf Bisschops: Raf Bisschops like it during workout. But besides that I I really like also to go outside and walk in the nature with my wife and also to do some workout cycling. So I I do have time besides my busy job both in the clinic and at ESGE and I really enjoy that.
Ian: Ian Well, that's great. Thank you again for being here. This has been a wonderful podcast. I appreciate your time and I wish you the best of the rest of your day.
Raf Bisschops: Raf Bisschops Same to you. Bye bye.
Ian Gralnek: Ian Gralnek Thank you for listening to this episode of Endoscopy Unplugged. If you found this podcast useful, please subscribe wherever you get your podcasts. And remember, they drop on the third Thursday of each month. To find out more about the European Society of Gastrointestinal Endoscopy, for example, to browse our scientific publications, visit our website at esge.com. And of course we'd love to hear your feedback. What would you like to hear more of? Send your thoughts to podcast at ESGE dot com. Thanks for listening and join us next time.